Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | LIPC | P11150 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21819814 | 0.87 | FFAR1 (0.35) | FFAR1LIPE | |
| SCHEMBL30154016 | 0.85 | FFAR1 (0.35) | FFAR1 | |
| SCHEMBL24896803 | 0.83 | LRRK2 (0.36) | LRRK2CYP1A2IRAK4LIPC | |
| SCHEMBL30384644 | 0.83 | LRRK2 (0.36) | LRRK2CYP1A2IRAK4LIPC | |
| SCHEMBL20371661 | 0.82 | FFAR1 (0.37) | FFAR1 | |
| SCHEMBL24896712 | 0.81 | CYP1A2 (0.34) | LRRK2CYP1A2FFAR1 | |
| SCHEMBL25239415 | 0.81 | CYP1A2 (0.35) | LRRK2CYP1A2FFAR1 | |
| SCHEMBL19626238 | 0.79 | DGAT1 (0.34) | FFAR1 | |
| SCHEMBL20154072 | 0.78 | UCHL1 (0.45) | — | |
| SCHEMBL22405990 | 0.78 | FFAR1 (0.34) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-3423445-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2020-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IKZF3, INTS9, CYP2C9 | LRRK2 2052/4885CYP1A2 279/4885FFAR1 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.